E
Xilio Therapeutics, Inc. XLO
$0.7002 -$0.031-4.24%
Recommendation
Sell
Prev Close
$0.7312
Volume
270,946
Avg Vol (90D)
2,845,257
Market Cap
$37.86M
Dividend & Yield
--
52-Week Range
$0.63 - $1.70
P/E (TTM)
--
EPS (TTM)
-$1.36
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Xilio Therapeutics (NASDAQ:XLO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
3/13/2025 - Ticker Report
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress
3/12/2025 - TipRanks Financial Blog
Xilio Therapeutics files $250M mixed securities shelf
3/11/2025 - The Fly
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
3/11/2025 - Zacks Investment Research
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year ...
3/11/2025 - GuruFocus
Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year
3/11/2025 - The Fly
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
3/11/2025 - Globe Newswire
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
2/24/2025 - GuruFocus
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
2/24/2025 - Globe Newswire
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)
2/13/2025 - TipRanks Financial Blog
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely
2/13/2025 - Simply Wall St
AbbVie and Xilio Therapeutics announce collaboration and option agreement
2/12/2025 - Seeking Alpha - Healthcare
AbbVie and Xilio Therapeutics Collaborate on Novel Tumor-Activated Immunotherapies
2/12/2025 - GuruFocus
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel ...
2/12/2025 - GuruFocus
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel ...
2/12/2025 - GuruFocus
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
2/12/2025 - GuruFocus
Xilio Therapeutics announces multiple masked T cell engager programs
2/12/2025 - The Fly
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
2/12/2025 - Globe Newswire
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
2/12/2025 - Globe Newswire
AbbVie and Xilio Therapeutics announce collaboration
2/12/2025 - The Fly
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
2/12/2025 - PR Newswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/3/2025 - GuruFocus
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/3/2025 - Globe Newswire
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 44.5% in January
1/31/2025 - Ticker Report
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update
1/30/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$6.34M
EBITDA (TTM)
-$58.00M
EBIT (TTM)
-$59.65M
Net Income (TTM)
-$58.24M
Balance Sheet
Total Assets (Q)
$71.08M
Total Debt (Q)
$8.14M
Total Liabilities (Q)
$53.48M
Book Value Per Share (Q)
$0.3846
Cash Flow
Cash from Operations (TTM)
-$18.38M
Cash from Investing (TTM)
-$36.00K
Cash from Financing (TTM)
$29.20M
Net Change in Cash (TTM)
$10.78M
Filings
Filing Date
Tuesday, March 11, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
-0.61
7-Day Total Return
-7.87%
30-Day Total Return
-33.94%
60-Day Total Return
-30.67%
90-Day Total Return
-25.61%
Year to Date Total Return
-34.56%
1-Year Total Return
-46.14%
2-Year Total Return
-77.00%
3-Year Total Return
-90.18%
5-Year Total Return
--
52-week Low
Feb 04, 2025 - $0.63
52-week High
Feb 12, 2025 - $1.70
Valuation
Market Cap
$37.86M - Nano Cap
Enterprise Value
-$9.29M
Price/Sales (TTM)
7.46
Price/Book (Q)
1.90
Dividends and Shares
Shares Outstanding
64.68M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
xiliotx.com
Phone Number
857-524-2466
Address
828 Winter Street
Waltham, MA 02451
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program... more
NASDAQ 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings